Summary by Moomoo AI
On July 9, 2024, 60 Degrees Pharmaceuticals, Inc. announced the enrollment of the first patient in a clinical trial at Tufts Medical Center for the treatment of Babesiosis using tafenoquine. This trial is significant as it is the first of its kind and aims to confirm the 80% cure rate observed in a previous Yale School of Public Health study. The earlier study, published in Clinical Infectious Diseases, showed promising results in a small group of immunosuppressed patients. While tafenoquine is currently approved for malaria prophylaxis under the name ARAKODA, it is not yet approved for the treatment or prevention of Babesiosis, a tick-borne illness that can be life-threatening, especially in the elderly and immunocompromised. The company's press release, which is...Show More